

1 **Association of CD7⁺CXCR3⁺ CAR T cells with long-term remission in R/R DLBCL**

2 Robin Bartolini^{1*}, Lionel Trueb^{2*}, Douglas Daoudlarian^{1*}, Victor Joo¹, Alessandra Noto¹,
3 Raphaël Stadelmann³, Bernhard Gentner^{2,4,5,6}, Craig Fenwick¹, Matthieu Perreau¹, Georges
4 Coukos^{2,4,5,6}, Giuseppe Pantaleo¹, Caroline Arber^{2,3,4,5,6}, Michel Obeid^{1#}

5 ¹Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
6 Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne,
7 Switzerland

8 ²Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
9 Oncology, Immuno-Oncology Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland

10 ³Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Departments of
11 Oncology and Laboratory Medicine, Hematology Service, Rue du Bugnon 46, CH-1011
12 Lausanne, Switzerland

13 ⁴Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.

14 ⁵Swiss Cancer Center Léman, Lausanne, Switzerland.

15 ⁶AGORA Cancer Research Center, Lausanne, Switzerland.

16 *contributed equally to this work

17

18 **≠Corresponding author:**

19 Pr. Michel Obeid, MD-PhD

20 Lausanne Center for Immuno-Oncology Toxicities LCIT

21 Immunology and Allergy Division, Rue du Bugnon 17, 1011 Lausanne, Switzerland

22 Centre Hospitalier Universitaire Vaudois (CHUV)

23 **Email:** michel.obeid@chuv.ch

24

25 **Key words:** Anti-CD19 CAR T cell infusion products, immune cell phenotypes, predictive

26 biomarkers, CXCR3, CD7, NKG2D, LAG-3, CD71.

27

28

29

30 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Abstract**

32 **Background.** CAR T-cell therapy is the standard of care for R/R DLBCL, but more than half
33 of patients fail to achieve long-term remission. Identification of cellular biomarkers in CAR T-
34 cell infusion products (IPs) that predict complete remission beyond six months may guide the
35 development of strategies to improve outcomes.

36 **Methods.** IPs from 13 R/R DLBCL patients were analyzed using a 39-marker mass cytometry
37 panel, comparing cell populations between long-term responders (R) and non-responders (NR).
38 Both unsupervised and supervised analyses were performed. Longitudinal blood samples were
39 analyzed for 30 days to track CAR T-cell subpopulation dynamics.

40 **Results.** At a median follow-up of 13.5 months, median progression-free survival (PFS) was
41 13.3 months (95% CI: 9.7-24.3) in R (n=8) versus 3.5 months (95% CI: 0.5-5.4) in NR (n=5).
42 The HR for PFS was 56.67 (95% CI: 7.3-439.3; P=0.0001). A subset of CD3⁺CXCR3⁺CD7⁺
43 CAR T-cells found in both CD4⁺ and CD8⁺ populations was significantly enriched in R and
44 expressed higher levels of perforin, granzyme B, and NKG2D (restricted to CD8⁺). NR had
45 more CXCR3⁺CD7⁺LAG3⁺ CAR T-cells. CD3, CD7, CXCR3, and NKG2D cell surface levels
46 were higher in R, whereas LAG3, Ki67, and CD71 were elevated in NR. A predictive cut-off
47 ratio of CD3⁺CXCR3⁺CD7⁺LAG3⁺CAR⁺ T-cells <0.83 and
48 CD3⁺CXCR3⁺CD7⁺NKG2D⁺CAR⁺ T-cells >1.034 yielded a predictive accuracy of 0.92.
49 Serum CXCL9 and CXCL10 levels were not different between groups.

50 **Conclusions.** Increased frequency of CAR T-cells expressing CD7, CXCR3 and NKG2D in R
51 versus LAG3 and CD71 in NR emerged as strong correlates of therapeutic outcome.

52

53

54 **Introduction**

55 Despite notable clinical successes, about half of all patients with relapsed and/or refractory
56 diffuse large B-cell lymphoma (R/R DLBCL) do not achieve long-term remissions with
57 currently available CAR T-cell therapy¹. Predictive factors determining the efficacy remain
58 incompletely understood. The phenotypic composition of infusion products (IPs) is important,
59 as defined T-cell subsets have been associated with enhanced antitumor activity *in vivo*².
60 Patients treated with axicabtagene ciloleucel (axi-cel), achieved higher complete response (CR)
61 rates when their IPs were enriched for CD8 memory T-cell phenotypes³. These memory-like T
62 cells are believed to confer sustained proliferative capacity and persistence leading to better
63 clinical outcomes.

64 Moreover, the expression of inhibitory receptors on CAR-T cells has been linked to therapeutic
65 failure. Human CAR-T cells with intrinsic PD-1 blockade overcome tumor-driven inhibition⁴.
66 Additionally, PD-1 inhibition enhanced the function of CAR-T cells in patient with R/R
67 DLBCL⁵. Notably, exhaustion markers like LAG-3 and TIM-3 on intratumoral CD8⁺ T cells
68 by day 7 post-infusion correlate with poorer outcomes in patients receiving axi-cel³. This
69 suggests that regulatory and exhausted T-cell phenotypes may limit the efficacy of CAR T-cell
70 therapy. Similar patterns have been reported in chronic lymphocytic leukemia (CLL), where
71 patients achieving durable remissions following CAR T-cell therapy received infusion products
72 with lower frequencies of CD8⁺ T cells co-expressing inhibitory receptors like PD-1, LAG-3,
73 and TIM-3⁶. Conversely, higher co-expression of these inhibitory receptors correlated with
74 suboptimal responses, highlighting the importance of T-cell fitness and the intricate balance
75 between activation and inhibition in driving successful outcomes^{6,7}.

76 These findings highlight the critical need for a deeper understanding of the phenotypic
77 characteristics that predict CAR T-cell efficacy. By identifying specific CAR T-cell phenotypes

78 associated with successful treatment outcomes, existing IPs and clinical treatment algorithms
79 can potentially be optimized to enhance patient outcomes. Moreover, data from correlative bed-
80 to-bench studies can be exploited for the development of next generation potency-enhanced
81 CAR T-cell products.

82
83 To address this knowledge gap, we performed a comprehensive analysis conducted an extensive
84 analysis of the cellular and phenotypic diversity within CAR T-cell infusion products using a
85 39-marker mass cytometry panel. The objective of this study was to identify predictive markers
86 of durable responses and to improve our comprehension of the factors influencing the long-
87 term efficacy of CAR T-cell therapy in patients with R/R DLBCL.

88

89 **METHODS**

90 **Patient Consent, Ethical Approval, and Sample Collection.** Participants provided informed
91 consent for the research use of their cells, blood samples, and data through a "consentement
92 général" process, ensuring data confidentiality. Enrollment followed Article 34 of the Swiss
93 Federal Law on Human Research, and the study received approval from the Cantonal Ethics
94 Committee (CER-VD). Biological samples were collected during routine clinical care, with
95 residual CAR T-cells obtained by washing the CAR T-cell infusion bag & line after infusion.
96 Peripheral blood mononuclear cells (PBMCs) were collected from treated patients at multiple
97 time points from week 1 to week 4 post-infusion.

98 **Mass Cytometry Analysis.** A mass cytometry panel comprising 39 markers was developed
99 and validated for this study with the corresponding fluorescently labeled antibody clones from
100 BD Biosciences (**Supplementary Table 1**). The analysis was compared to healthy volunteer
101 data to establish baselines. This panel enabled high-dimensional analysis of cellular

102 phenotypes, offering insights into IP composition and immune cell dynamics in CAR T-cell
103 therapy recipients.

104 **Study Design and Population.** This observational study was conducted at the CHUV's
105 Immuno-Oncology and Immunology and allergy Service from January 2020 to May 2024. The
106 final analysis included 13 patients with relapsed/refractory (R/R) DLBCL receiving standard of
107 care CAR T-cell therapy and follow up (**Supplementary Figure 1**).

108 **Oncologic Response Assessment.** CAR T-cell therapy efficacy was assessed using PET/CT
109 scans at baseline, and 1-, 3- and 6-months post-infusion.

110 **Response Definitions.** Responders were those with no relapse on PET/CT for at least six
111 months post-infusion. Non-responders either did not respond at the 30-day evaluation or
112 experienced disease progression before the six-month follow-up.

113 **Statistical Analysis.** Statistical analyses were performed using GraphPad Prism 10.1.2 and
114 MATLAB R2023b. ROC curve analysis and clustering were conducted, with optimal cutoffs
115 determined using Youden's index. Cox proportional hazard model was performed using R and
116 "*survival package*". Clustering was performed using k-means clustering MATLAB.

117

118 **RESULTS**

119 **Patient clinical characteristics.**

120 A total of 41 patients treated with CAR T-cell therapy at the University Hospital of Lausanne
121 (CHUV) were identified. CAR-T infusion data were analyzed for 13 patients with R/R DLBCL
122 (study flowchart **Supplementary Figure 1**). Patient characteristics are summarized in **Table 1**.

123 The median follow-up was 13.5 months at the data cut-off date (June 15, 2024). The median
124 patient age was 61 years (range 28-78), with 38% aged >65 years and 77% male (n=10/13).

125 The majority of patients (54%, n=7/13) had stage III or IV disease. Treatments included
126 axicabtagene ciloleucel (axi-cel) (85%, n=11/13) and tisagenlecleucel (tisa-cel) (15%, n=2/13).

127 Cytokine release syndrome (CRS) was observed in 85% of patients, with 69% exhibiting mild
128 (grades 1-2) and 15% demonstrating severe (grades 3 or higher) CRS, according to the ASTCT
129 Consensus grading system⁸. The most common late (after 30 days) hematologic toxicity
130 (ICAHT) was grade 3 or higher thrombocytopenia (38%) and neutropenia (31%), only grade 3
131 or higher have been reported in the **Supplementary Table 2**. Regarding CRS treatment, 85%
132 received only tocilizumab (TCZ), 38% received corticosteroids (CS) and 8% received
133 canakinumab (CAN). Four patients were treated in second line, all others in third or higher line,
134 and 31% (n=4/13) had relapsed after autologous stem cell transplantation (**Supplementary**
135 **Table 2**).

136

137 **Distinct CAR T-cell populations in infusion products associated with long-term remission**

138 We used a 39-marker panel to identify CAR T-cell populations associated with long-term
139 remission. We first examined the frequencies of total CAR⁺CD4⁺ and CAR⁺CD8⁺ T-cells and
140 the CD4/CD8 ratio but found no significant association with outcomes (**Supplementary Figure**
141 **2**). We next extended our analysis to other markers and evaluated their frequencies and
142 expression levels within the total CAR⁺CD3⁺ compartment and the CAR⁺CD3⁺CD4⁺ and
143 CAR⁺CD3⁺CD8⁺ subsets. Among all analyzed markers, we observed significant differential
144 expression of LAG3, Ki67, CD71, CXCR3, CXCR5, CD3, and CD7 between responders (R)
145 and non-responders (NR) (**Figure 1, Supplementary Figure 3**). Specifically, IPs of NR
146 contained significantly higher proportions of LAG3⁺, Ki67⁺, and CD71⁺ CAR T-cells in total
147 CD3⁺, CD3⁺CD4⁺, and CD3⁺CD8⁺ compartments, and mean metal intensity (MMI) of these
148 markers was also significantly increased. Conversely, CAR T-cells in IPs of R expressed higher
149 levels of CD3, CD7, CXCR3, and CXCR5 by MMI. Notably, NKG2D expression was higher
150 in R compared to NR but only within the CD8⁺ compartment, consistent with NKG2D's
151 restriction to CD8⁺ T-cells. Analysis of these markers alone (on the total CAR⁺CD3⁺

152 compartment) demonstrated significant performance in discriminating between R and NR using
153 receiver operating characteristic (ROC) curve analyses, with area under the curve (AUC) values
154 ranging from 0.85 to 0.975 and p-values from 0.0404 to 0.0054 (**Supplementary Figure 4**)

155

156 **Identification of a responder-enriched CD3⁺CXCR3⁺CD7⁺CAR⁺ T-cell population in**
157 **infusion products.**

158 Next, we investigated whether these identified markers were co-expressed, defining a
159 population that could predict long-term remission. Initially, we used unsupervised UMAP
160 analysis, which divided the CAR⁺CD3⁺ compartment into two clusters: CD4⁺ cells (low
161 NKG2D expression) and CD8⁺ cells. In the CD4⁺ cluster, NR had higher frequencies of
162 populations C4-6 and C4-7, characterized by low CXCR3 and CD7 but high CD71; C4-7 also
163 had elevated Ki67 and LAG3 (**Supplementary Figure 5**). In the CD8⁺ compartment, cluster
164 C8-3 was enriched in R, expressing high CXCR3 and CD7 but low Ki67 and LAG3.
165 Conversely, cluster C8-6, enriched in NR, showed lower CXCR3, CD7, and NKG2D but higher
166 LAG3 compared to C8-3 (**Supplementary Figure 5**). Given the critical importance of CXCR3
167 and CD7 in defining R and NR, we focused our supervised analysis on CAR⁺CXCR3⁺CD7⁺
168 double-positive cells. In R, CXCR3⁺CD7⁺ (CD3⁺CAR⁺) cells averaged 85%, compared to 65%
169 in NR. In the CD8⁺ compartment, CXCR3⁺CD7⁺ cells represented 90% of CD8⁺CAR⁺ cells in
170 R versus 75% in NR (**Figure 2A**).

171

172 **Phenotypic characterization of the CD3⁺CXCR3⁺CD7⁺CAR⁺ T-cell population.**

173 We further characterized the CXCR3⁺CD7⁺ double-positive population by comparing co-
174 expression of various other markers to that of CXCR3⁺CD7⁻, CXCR3⁻CD7⁺, and CXCR3⁻CD7⁻
175 populations. The CXCR3⁻CD7⁻ population expressed the lowest levels of all markers analyzed,
176 except for CD71, which was highly expressed compared to other populations. The

177 CXCR3⁺CD7⁺ cells expressed the highest levels of perforin, granzyme B, and NKG2D,
178 indicating the strongest effector potential (**Supplementary Figure 6**). After identifying this
179 double-positive population in both IPs and longitudinal samples (**Supplementary Figure 7**),
180 we investigated whether other markers on CXCR3⁺CD7⁺ cells were differentially expressed
181 between R and NR. Among all analyzed markers, we again observed significant differences in
182 the expression of CD3, CD7, Ki67, NKG2D, CD71, and LAG3 (**Supplementary Figure 8**).
183 We incorporated these markers one by one into the CXCR3⁺CD7⁺ population.
184 CXCR3⁺CD7⁺LAG3⁺ cells were twice as frequent in the IPs of NR (40% of CD3⁺CAR⁺ cells)
185 compared to R (20%), a difference also observed in the CD4⁺ and CD8⁺ compartments (**Figure**
186 **2B**). Conversely, CXCR3⁺CD7⁺NKG2D⁺ cells were significantly more frequent in the CD8⁺
187 compartment of R, reaching 80% of CD3⁺CD8⁺CAR⁺ T-cells compared to only 45% in NR
188 (**Figure 2C**). No significant differences were observed in the frequency of
189 CXCR3⁺CD7⁺CD71⁺ cells between groups (**Figure 2D**). Interestingly, while the CXCR3⁺CD7⁺
190 population was also observed in the circulation of healthy individuals, these cells completely
191 lacked CD71 expression, exhibited very low LAG3 levels, and showed NKG2D levels
192 comparable to those observed in NR. NKG2D upregulation in CD3⁺CD8⁺CAR⁺ T-cells seems
193 to be exclusive to R. This highlights profound phenotypic differences between normal memory
194 T-cells and CAR T-cells, suggesting that the CXCR3⁺CD7⁺CAR⁺ population in responders is
195 uniquely endowed with cytotoxic capabilities essential for effective antitumor responses.

196

197 **The predictive value of marker ratios for six-month progression-free survival.**

198 Given the established correlation between specific markers and patient survival, we sought to
199 determine whether the balance between positive and negative subpopulations for CD71, LAG3,
200 and NKG2D within the CXCR3⁺CD7⁺ subset influences the prediction of treatment response.
201 We evaluated the ratios of CD71, LAG3, and NKG2D MMI within the CXCR3⁺CD7⁺

202 population across all CAR⁺ T-cells as well as within CAR⁺CD4⁺ and CAR⁺CD8⁺ subsets, to
203 assess their predictive performance. The analysis demonstrated that all ratios—except for
204 NKG2D in CD3⁺ cells and CD71⁺ in CAR⁺CD8⁺ cells—showed statistically significant
205 differences between R and NR. Optimal cutoff values were identified using the Youden index
206 and utilized to reclassify patient responses using forementioned ratios, all markers except
207 NKG2D in CD3 and CD71 in CAR⁺CD8⁺ had ROC that were predictive, with accuracies
208 ranging from 0.77 to 0.92. Notably, LAG3 positivity and NKG2D negativity within the
209 CXCR3⁺CD7⁺ population were linked to poorer PFS outcomes (**Figure 3**). We then examined
210 the expression levels of previously identified significant markers—CXCR3, CD7, NKG2D,
211 LAG3, and Ki67—on various populations based on CD3⁺, CD4⁺, CD8⁺, and CXCR3⁺CD7⁺
212 subsets to determine whether these levels could predict long-term remission. Our findings
213 revealed that all marker MMIs, except for Ki67 in the CD4⁺CXCR3⁺CD7⁺ and
214 CD8⁺CXCR3⁺CD7⁺ subsets, demonstrated substantial capacity for differentiating between R
215 and NR through ROC curve analyses. The AUC values ranged from 0.85 to 1, with p-values
216 from 0.0034 to 0.0415 (**Supplementary Figure 9**). Notably, CD7 MMI exhibited optimal
217 performance, reaching an AUC of 1 in CD8⁺ cells (p = 0.0034). A comparable outcome was
218 obtained using frequencies of marker expression (**Supplementary Figure 10**). Using the ROC
219 based approach on both MMI (**Supplementary Figure 11**) and frequencies (**Supplementary**
220 **Figure 12**), KM analyses revealed that most markers significantly predicted six-month PFS.
221 We calculated accuracy, negative predictive value (NPV), positive predictive value (PPV),
222 sensitivity, and specificity for these predicted PFS values. The most effective predictors were
223 CD7 MMI in both CD8⁺ and CD8⁺CXCR3⁺CD7⁺ CAR-T cells. Other markers demonstrated
224 satisfactory accuracy, ranging from 0.77 to 0.92. Notably, several markers exhibited PPV or
225 NPV values of 1, indicating a robust correlation between their expression and six-month PFS.
226

227 **Clustering analysis for predicting PFS**

228 To further evaluate the predictive potential of specific CAR-T subpopulation frequencies and
229 marker expression levels independently of the known PFS, we assessed whether CXCR3 and
230 CD7 MMI in total CD3⁺CAR⁺, CD3⁺CD4⁺CAR⁺, or CD3⁺CD8⁺CAR⁺ T cells could
231 discriminate between R and NR. One-dimensional k-means clustering was used to categorize
232 MMI expression into two clusters. The predictive accuracy of these clusters for six-month PFS
233 was then evaluated using KM curves. This approach yielded statistically significant results,
234 with p-values ranging from 0.001 to 0.016 for all clusters except CD8⁺CD7⁺ MMI (p = 0.1646)
235 (**Supplementary Figure 13a–f**). These findings indicate that elevated expression levels of
236 CXCR3 and CD7 are associated with enhanced PFS in most T-cell subsets examined. We also
237 applied the same clustering approach to differentiate between R and NR based on the
238 simultaneous expression of multiple markers—CXCR3, CD7, CD71, NKG2D, LAG3, and
239 Ki67 MMI—on the CD3⁺CXCR3⁺CD7⁺ population (**Supplementary Figure 14a**). The
240 silhouette value approach determined an optimal two-cluster solution (**Supplementary Figure**
241 **14b**), identifying two distinct clusters: Cluster 1 consisted of four NR, while Cluster 2 included
242 all eight R and one NR. t-SNE visualization showed that the four NR in Cluster 1 clustered
243 closely, whereas the one NR in Cluster 2 was closer to the R (**Supplementary Figure 14c**).
244 This underscores the notable phenotypic distinction of infused CAR-T cells between most NR
245 and R.

246

247 **Correlation analysis of marker expression**

248 The clustering analysis demonstrated clear distinctions of CAR T-cell phenotypes independent
249 of infusion product type; NR clustered together regardless of the presence of a CD28 or 4-1BB
250 co-stimulatory domain. This pattern suggests that certain markers are correlated, forming two
251 distinct phenotypes associated with response status. The NR phenotype is characterized by high

252 expression of LAG3 and CD71 with low levels of CXCR3 and CD7, while the R phenotype
253 exhibits high CXCR3 and CD7 with low LAG3 and CD71.

254 A correlation matrix of all 39 markers expression across CAR⁺CD3⁺, CD4⁺, and CD8⁺
255 compartments revealed intriguing population dynamics. Specifically, positive correlations were
256 observed between CD7 and CXCR3, and between CD71 and LAG3 expressing CAR T-cells.
257 Negative correlations were noted between CXCR3 and LAG3, CD71 and NKG2D, and
258 NKG2D and LAG3 expression (**Supplementary Figures 15–17**). These negative correlations
259 imply mutual exclusivity among certain markers—for example, high CXCR3 expression
260 coincided with low LAG3 expression. A positive correlation was observed between the
261 frequencies of LAG3 and Ki67-expressing CAR T-cells across all T cell subsets, including total
262 CD3⁺, CD4⁺, and CD8⁺ populations. Furthermore, within the CD8⁺ CAR T-cell subset, a
263 significant positive correlation was identified between the frequencies of CXCR3 and NKG2D-
264 expressing CAR T-cells (**Supplementary Figures 18-20**).

265

266 **Longitudinal analysis of the CXCR3⁺CD7⁺ population post-infusion**

267 After characterizing the CXCR3⁺CD7⁺ population in IPs of both R and NR, and identifying
268 markers linked to long-term remission, we evaluated the population dynamics in circulation up
269 to 30 days post-infusion. Our focus was on the frequency of these cells and alterations in marker
270 expression. At baseline, all patients were lymphopenic. Between Day 3 and 7 post-infusion,
271 CD3⁺ cell frequencies increased in both R and NR. However, while there was no difference in
272 the expansion of CAR⁻ T-cells, we observed a substantial increase in CAR⁺ T-cells only in R
273 (**Supplementary Figure 21**). Specifically, this expansion was driven by CXCR3⁺CD7⁺ CAR⁺
274 T-cells, which reached 12.0% of total CD45⁺ cells at Days 7, compared to 2.7% in NR (**Figure**
275 **4a**). In R, this represented a tenfold increase compared to Day 3, whereas expansion was
276 minimal in NR. In contrast, the frequencies of CXCR3⁻CD7⁺, CXCR3⁺CD7⁻, and double-

277 negative (CXCR3⁻CD7⁻) CAR⁺ T-cells remained low and were similar between R and NR
278 (**Supplementary Figure 22**). Between Days 3 and 10, CXCR3⁺CD7⁺ CAR⁺ T-cells in R
279 showed significant increases in CXCR3 and Ki67 expression levels, suggesting enhanced
280 proliferation and activation. These increases were not observed in NR (**Figure 4b**). On Day 7,
281 CXCR3⁺CD7⁺ CAR⁺ T-cells in R exhibited increased expression of CXCR3 and Ki67
282 compared to NR, while LAG3 levels in NR were non significantly elevated relative to R
283 (**Figure 4 c-e**). Circulating levels of CXCR3-binding chemokines, CXCL9 and CXCL10, were
284 similarly elevated in both R and NR and did not increase during the expansion phase (**Figures**
285 **4f-g**). These findings indicate that enhanced activation and proliferation of CXCR3⁺CD7⁺
286 CAR⁺ T-cells are essential for a favorable therapeutic outcome and occur independently of
287 circulating CXCR3-binding chemokine levels.

288 From Day 10 onwards, we observed a significant elevation of perforin levels in CXCR3⁺CD7⁺
289 CD3⁺ CAR⁺ T-cells in R. This increase was not due to changes in CD4⁺ or CD8⁺ frequencies,
290 as proportions of CD4⁺CXCR3⁺CD7⁺ and CD8⁺CXCR3⁺CD7⁺ cells remained similar between
291 R and NR (**Supplementary Figure 23**). Apart from perforin, CXCR3, LAG3, and Ki67, no
292 other markers showed a comparable expression pattern over time. These findings suggest that
293 in R, the CXCR3⁺CD7⁺ CAR⁺ T-cell population not only expands significantly post-infusion,
294 but also shows enhanced proliferative and cytotoxic capabilities. The absence of similar
295 changes in NR underscores the potential role of dynamic shifts in the CXCR3⁺CD7⁺ population
296 in mediating effective antitumor responses and achieving long-term remission.

297

298 **Discussion**

299 Our study provides novel insights into the phenotypic characteristics of CAR T-cells in standard
300 of care IPs that are associated with long-term remission in patients with R/R DLBCL by
301 identifying specific markers and cell populations that distinguish R from NR. These findings

302 could have substantial implications for predicting treatment outcomes, optimizing CAR-T cell
303 manufacturing processes, and ultimately improving patient outcomes. We observed that the
304 overall CD4/CD8 ratio did not correlate with outcomes, aligning with previous reports
305 suggesting that quantitative global measures of T cell lineage subset content alone may not
306 sufficiently predict clinical responses to CAR T-cell therapy⁹. This prompted a deeper
307 exploration into phenotypic and functional characteristics of CAR T-cell populations. Here, we
308 report differential expression of activation and exhaustion markers between R and NR. NR had
309 higher levels of LAG3, Ki67, and CD71, indicating a state of enhanced activation and potential
310 early exhaustion of CAR-T cells prior to infusion. LAG3 is an inhibitory receptor associated
311 with T cell exhaustion and impaired effector function¹⁰. It was reported that the disruption of
312 LAG3 in CAR T cells enhanced their anti-tumor activity by improving their proliferation and
313 persistence, leading to improved tumor eradication in preclinical models^{11,12}, highlighting the
314 potential of targeting LAG3 as a tool to improve CAR T-cell efficacy, either by direct
315 modification of CAR-T cells or by combining CAR T-cell therapy with LAG3 inhibitors.
316 Elevated levels of Ki67 and CD71 indicate active proliferation and increased metabolic
317 demand, leading to replicative senescence and reduced persistence after infusion¹³, which may
318 contribute to suboptimal clinical outcomes.

319 In contrast, R expressed higher levels of CD3, CD7, CXCR3 and NKG2D. CXCR3 is involved
320 in T-cell trafficking and homing to sites of inflammation and malignancy^{14,15}, suggesting
321 enhanced migratory capabilities of CAR T cells in R. NKG2D is an activating receptor
322 recognizing stress-induced ligands on tumor cells, contributing to increased cytotoxicity^{16,17}. It
323 was reported that NKG2D-expressing CAR T-cell therapies, either alone or in combination with
324 other treatments like IL-15 or radiotherapy, may offer an effective approach to enhancing CAR
325 T-cell therapy's efficiency against various cancers¹⁸. The elevated expression of these receptors
326 on CAR T cells suggests that CAR T cells from R are likely endowed with enhanced migratory

327 and effector functions, which facilitates effective tumor localization and eradication. Notably,
328 the CXCR3⁺CD7⁺ double-positive population, enriched in R, was characterized by the strongest
329 effector potential with detection of high perforin, granzyme B, and NKG2D levels. In contrast,
330 IPs of NRs contained a higher frequency of CXCR3⁺CD7⁺LAG3⁺CAR⁺ T cells, suggesting
331 CAR-T cell susceptibility to inhibitory signals that might limit efficacy even within potentially
332 beneficial subsets.

333 Our results demonstrate that certain markers—such as CD7 MMI in CD8⁺ cells—were strongly
334 predictive for six-month progression-free survival. ROC analyses and clustering approaches
335 reinforced the utility of these markers for distinguishing R from NR. R experienced a significant
336 expansion of CXCR3⁺CD7⁺CAR⁺ T cells post-infusion, accompanied by increased perforin,
337 Ki67 and CXCR3 expression, indicating enhanced proliferation and activation, necessary
338 prerequisites for achieving sustained remission¹⁹. The absence of these features in NR, along
339 with upregulated LAG3, may contribute to poorer outcomes.

340 Implementing biomarker assessments, such as incorporating key markers in flow cytometry
341 panels, could improve CAR T-cell product evaluation, inform real-time clinical decisions, and
342 aid in patient stratification. The identified markers could also guide modifications to the CAR
343 T-cell manufacturing process—such as enriching for favorable markers (e.g.,
344 CXCR3⁺CD7⁺NKG2D⁺) and depleting those associated with exhaustion (e.g., LAG3⁺).
345 Additional strategies may include engineering CAR T cells to downregulate inhibitory
346 receptors such as LAG3 or overexpress activating receptors like NKG2D, thereby enhancing
347 antitumor activity. The administration of checkpoint inhibitors targeting LAG3 at an early stage
348 may prove beneficial for patients with suboptimal expansion or an elevated level of inhibitory
349 receptors following infusion. These questions require assessment in carefully designed clinical
350 trials.

351 However, our study's relatively small sample size may limit the generalizability of the findings.
352 Future studies involving larger, multicenter cohorts are needed to validate these biomarkers.
353 Incorporating functional assays alongside phenotypic analysis would also provide a more
354 comprehensive understanding of their roles in mediating therapeutic effects. The immune
355 microenvironment and patient-specific factors may also influence CAR T-cell efficacy,
356 suggesting that a multifaceted approach is needed to fully optimize therapy.

357 This study underscores the value of phenotypic characterization for predicting clinical
358 outcomes in CAR T-cell therapy. By integrating these biomarkers into clinical protocols, we
359 can enhance patient selection, tailor manufacturing processes, and implement targeted
360 interventions to improve the efficacy of CAR T-cell treatments. Future research should focus
361 on validating and operationalizing these markers to maximize their potential in personalized
362 medicine.

363 **Figures legend**

364 **Figure 1: Marker expression in CD3⁺ CAR⁺ T-cells**

365 Expression of CD3, CD7, CD71, CXCR3, CXCR5, Ki67, LAG3 and NKG2D in CD3⁺CAR⁺
366 T-cells, expressed both as MMI **(a)** and as frequency **(b)** of the parent population. Marker
367 expression was measured in the total CD3⁺ population **(a-b)**, in the cytotoxic **(c-d)** (CD3⁺CD8⁺)
368 and in the helper **(e-f)** (CD3⁺CD4⁺) compartment. Responders=blue, n=8. Non-responders=red,
369 n=5. Statistical significance was determined using the Mann-Whitney U-Test, with significance
370 levels indicated as *p<0.05 and **p<0.01.

371 **Figure 2: Frequencies of double and triple positive CAR T-cells. (a)** Frequencies of double-
372 positive CXCR3⁺CD7⁺ cells as a percentage of CAR⁺CD3⁺, CAR⁺CD3⁺CD4⁺, and
373 CAR⁺CD3⁺CD8⁺ cells in responders (blue, n=8) vs. non-responders (red, n=5), **(b-d)**
374 Frequencies of triple-positive CXCR3⁺CD7⁺ (LAG3⁺NKG2D⁺CD71⁺) cells as a percentage of

375 CAR⁺CD3⁺, CAR⁺CD3⁺CD4⁺, and CAR⁺CD3⁺CD8⁺ cells in responders (blue, n=8) vs. non-
376 responders (red, n=5). Memory T-cell frequencies from healthy controls (yellow, n=10) are
377 provided as a baseline reference. Statistical significance determined via Mann-Whitney U-Test,
378 with *p<0.05 and **p<0.01.

379

380 **Figure 3: Marker ratios as predictive tools for six-month PFS**

381 **(a)** Ratios of positive/negative populations for CD71, LAG3, and NKG2D in
382 CAR⁺CXCR3⁺CD7⁺CD3⁺ **(a)**, CD3⁺CD4⁺ **(b)**, and CD3⁺CD8⁺ **(c)** cells in responders (blue,
383 n=8) vs. non-responders (red, n=5). NKG2D in CD4⁺ is excluded due to lack of expression.
384 Statistical significance determined by Mann-Whitney U-Test (*p<0.05, **p<0.01), **(d)**
385 Summary table of predictive power using marker ratios calculated with optimal cutoff values
386 determined via the Youden index. New predicted PFS accuracies, positive predictive value
387 (PPV), negative predictive value (NPV), sensitivities, and specificities are reported. **(e-f)** ROC
388 and AUC for the ratio of LAG3 in CD4⁺ and NKG2D in CD8⁺ and **(g-h)** association of the
389 respective ratio cutoff to progression free survival.

390

391 **Figure 4: Longitudinal analysis of CXCR3⁺CD7⁺ CD3⁺CAR⁺ T-cell frequency and marker** 392 **expression**

393 **(a)** Frequency of CAR⁺CD3⁺CXCR3⁺CD7⁺ cells in patient circulation (% of total CD45⁺
394 events) from Day 3 to Day 30 post-infusion (responders in blue, non-responders in red), **(b)**
395 Fold change in frequency of CXCR3⁺CD7⁺ (CAR⁺CD3⁺, % of total CD45⁺ events) from Day 3
396 to Day 10, comparing responders (n=8, blue) to non-responders (n=5, red) **(c-d)** Paired analysis
397 of CXCR3 (as MMI), Ki67 and LAG3 expression fluctuations (as frequency) in the
398 CXCR3⁺CD7⁺ population in responders (blue) and non-responders (red) between Days 3 and
399 10. **(e)** Associated graphs showing fold change in CXCR3, Ki67 and LAG3 MMI between Days

400 3 and 7. **(f-g)** Levels of CXCR3-binding chemokines CXCL9 and CXCL10 in circulation of
401 responders (blue) and non-responders (red) at Day 0 (infusion), Day 4, and Day 10 post-
402 infusion, with associated graphs showing fold changes in cytokine levels from Day 4 to Day
403 10. Statistical significance was assessed using the Mann-Whitney U-Test, with significance
404 levels indicated as * $p < 0.05$ and ** $p < 0.01$. The line shown within each box plot represents the
405 median.

406

407 **Acknowledgements**

408 This work was supported by the strategic plan of the CHUV. We would like to express our
409 gratitude to all the patients who generously contributed their time and samples for this project.

410

411 **Author contributions**

412 MO designed the study and supervised the analysis. MO, RB and DD drafted the manuscript.
413 MO, RB and DD had full access to all data in the study and take responsibility for its integrity
414 and accuracy. MO, DD, RB, LT and CA collected the data. AN, CF, MP, GP and MO developed
415 the CAR T-cell panel. RB, DD, VJ, CA, BG, LT and MO analyzed, interpreted and discussed
416 the data. LT, RS and CA recruited patients and supervised the clinical treatments. MO
417 participated in the clinical treatments. RB, DD, VJ and MO prepared the figures. GC and GP
418 participated in the scientific discussion. The manuscript was reviewed and approved by all
419 authors before submission.

420

421 **Conflict of interest**

422 MO received honoraria and speaker fees from Moderna, Roche and BMS. C.A. holds patents
423 and provisional patent applications in the field of engineered T cell therapies. C.A. receives
424 licensing fees and royalties from Immatics (through previous institution Baylor College of

425 Medicine), participated in advisory boards for Kite/ Gilead, Janssen and Celgene/ BMS,
426 received sponsored travel from Gilead (through current institution Lausanne University
427 Hospital (CHUV). G.C. has received honoraria from Bristol-Myers Squibb. CHUV has
428 received honoraria for advisory services provided by G.C. to Iovance and EVIR. G.C. has
429 received royalties from the University of Pennsylvania for CAR T cell therapy licensed to
430 Novartis and Tmunity Therapeutics. G.C. has received royalties from the Ludwig Institute for
431 Cancer Research, UNIL and CHUV for NeoTIL intellectual property previously licensed to
432 Tigen Pharma. G.C. is inventor in technologies related to T cell expansion and engineering for
433 T cell therapy. RS participated in advisory boards for Janssen, Celgene/ BMS, AbbVie, Takeda
434 and Incyte.

435

436 **Data sharing statements**

437 The datasets supporting the results of this study are not publicly available. Requests for access
438 to the dataset will be granted upon reasonable request to the principal investigator. Study data
439 will be managed, stored, shared, and archived according to CHUV standard operating
440 procedures to ensure the continued quality, integrity, and utility of the data.

441

442 **References**

- 443 1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse
444 Large B-Cell Lymphoma. *N Engl J Med* 2019;380(1):45-56. DOI: 10.1056/NEJMoa1804980.
- 445 2. Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells
446 derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.
447 *Leukemia* 2016;30(2):492-500. DOI: 10.1038/leu.2015.247.
- 448 3. Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products
449 associated with efficacy and toxicity in patients with large B cell lymphomas. *Nat Med*
450 2020;26(12):1878-1887. DOI: 10.1038/s41591-020-1061-7.
- 451 4. Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1
452 checkpoint blockade resist tumor-mediated inhibition. *J Clin Invest* 2016;126(8):3130-44. DOI:
453 10.1172/JCI83092.

- 454 5. Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor
455 (CAR)-modified T cells: refueling the CAR. *Blood* 2017;129(8):1039-1041. DOI: 10.1182/blood-
456 2016-09-738245.
- 457 6. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19
458 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med*
459 2018;24(5):563-571. DOI: 10.1038/s41591-018-0010-1.
- 460 7. Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know
461 so far. *Nat Rev Clin Oncol* 2023;20(6):359-371. DOI: 10.1038/s41571-023-00754-1.
- 462 8. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release
463 Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow*
464 *Transplant* 2019;25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758.
- 465 9. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19
466 chimeric antigen receptors. *Nat Rev Clin Oncol* 2013;10(5):267-76. DOI:
467 10.1038/nrclinonc.2013.46.
- 468 10. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and
469 CTLA-4: breakthroughs or backups. *Nat Immunol* 2019;20(11):1425-1434. DOI:
470 10.1038/s41590-019-0512-0.
- 471 11. Zhang Y, Zhang X, Cheng C, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. *Front*
472 *Med* 2017;11(4):554-562. DOI: 10.1007/s11684-017-0543-6.
- 473 12. Zou F, Lu L, Liu J, et al. Engineered triple inhibitory receptor resistance improves anti-tumor
474 CAR-T cell performance via CD56. *Nat Commun* 2019;10(1):4109. DOI: 10.1038/s41467-019-
475 11893-4.
- 476 13. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol*
477 2015;15(8):486-99. DOI: 10.1038/nri3862.
- 478 14. Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha
479 (SIRPalpha) and CD47: structure, function, and therapeutic target. *Annu Rev Immunol*
480 2014;32:25-50. DOI: 10.1146/annurev-immunol-032713-120142.
- 481 15. Groom JR, Luster AD. CXCR3 in T cell function. *Exp Cell Res* 2011;317(5):620-31. DOI:
482 10.1016/j.yexcr.2010.12.017.
- 483 16. Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged Persistence of
484 Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and
485 Ways Forward. *Front Immunol* 2020;11:702. DOI: 10.3389/fimmu.2020.00702.
- 486 17. Lanier LL. NKG2D Receptor and Its Ligands in Host Defense. *Cancer Immunol Res* 2015;3(6):575-
487 82. DOI: 10.1158/2326-6066.CIR-15-0098.
- 488 18. Mai Q, He B, Deng S, et al. Efficacy of NKG2D CAR-T cells with IL-15/IL-15Ralpha signaling for
489 treating Epstein-Barr virus-associated lymphoproliferative disorder. *Exp Hematol Oncol*
490 2024;13(1):85. DOI: 10.1186/s40164-024-00553-z.
- 491 19. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucef CAR T-Cell Therapy in
492 Refractory Large B-Cell Lymphoma. *N Engl J Med* 2017;377(26):2531-2544. DOI:
493 10.1056/NEJMoa1707447.

494

Graphical Abstract

Identification of phenotypic markers within CAR+ T-cell products that predict long-term remission in DLBCL patients





Table 1


	N=13	% within cohort
<u>Age</u>		
Median	61	
≥ 65 years	6	46%
<u>Gender</u>		
Female	3	23%
Male	10	77%
<u>Tumor Type</u>		
DLBCL	13	100%
<u>Initial Stage</u>		
I-II	6	46%
III-IV	7	54%
<u>CAR T-cell type</u>		
Axicabtagene ciloleucel	11	85%
Tisagenlecleucel	2	15%
<u>Cytokines release Syndrome (CRS)</u>		
<u>Grading</u>		
No CRS	2	15%
G1-G2	10	77%
G3-G4	1	15%
G5	0	0%
<u>Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)</u>		
<u>Grading</u>		
No ICANS	6	46%
G1-G2	3	23%
G3-G4	4	31%
G5	0	0%
<u>Immune Effector Cell-Associated Hematological Toxicity (ICAH)</u>		
<u>Late (>30 days)</u>		
Pancytopenia	2	15%
Anemia	2	15%
Thrombocytopenia	5	38%
Neutropenia	4	31%
<u>Immunosuppressive treatment</u>		
Corticosteroids (CS)	5	38%
Tocilizumab (TCZ)	11	85%
Canakinumab (CAN)	1	8%

Figure 1


a)




b)




c)



d)



e)



f)




Figure 2






Figure 3




d)

Population of CarT+	Marker	Cutoff to be R		ROC AUC	P AUC	Accuracy	PPV	NPV	Sensitivity	Specificity
		Sign	Cutoff							
CD3+ CXCR3+ CD7+	CD71	<	4.74	0.9	0.0192	0.85	0.88	0.80	0.88	0.80
	LAG3	<	0.83	0.95	0.0084	0.92	0.89	1.00	1.00	0.80
	NKG2D	>	1.034	0.775	0.1073	0.69	1.00	0.56	0.50	1.00
CD4+ CXCR3+ CD7+	CD71	<	5.14	0.9	0.0192	0.85	0.88	0.80	0.88	0.80
	LAG3	<	0.5601	0.9	0.0192	0.92	0.89	1.00	1.00	0.80
CD8+ CXCR3+ CD7+	CD71	<	4.058	0.825	0.057	0.77	1.00	0.63	0.63	1.00
	LAG3	<	0.7132	0.925	0.0128	0.85	1.00	0.71	0.75	1.00
	NKG2D	>	3.188	0.975	0.0054	0.92	1.00	0.83	0.88	1.00


e)



f)



g)



h)




Figure 4

